Olszewski AJ, et al. - Researchers evaluated the relationship between time from diagnosis to chemotherapy and overall survival in diffuse large B-cell (DLBCL), Burkitt (BL), mantle cell (MCL) and peripheral T-cell lymphoma (PTCL), using National Cancer Data Base records of 130,549 patients treated in 2004–2014. Findings suggested that high-risk features uncaptured by standard prognostic assessments could be reflected by time from diagnosis to treatment. Patients who need urgent therapy to improve external validity and detect treatment effects in high-risk groups ought to be accommodated in the clinical trials.